![MMAE-[d8]](https://resource.bocsci.com/structure/2070009-72-0.gif)
Inquiry Basket
CAS No.: 1826843-81-5
Cat No.: BADC-01602
4.5 
Trastuzumab deruxtecan is an antibody-drug conjugate consisting of humanized anti-HER2 antibody and a topoisomerase I inhibitor payload. Trastuzumab deruxtecan has been used in the research of HER2 expressing solid tumor therapy.
Structure of 1826843-81-5
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00023 | Trastuzumab emtansine | 1018448-65-1 | |
| BADC-01615 | Trastuzumab duocarmazine | 1642152-40-6 | |
| BADC-01347 | Trastuzumab-MC-MMAE |
Trastuzumab deruxtecan
Required fields are marked with *
Trastuzumab deruxtecan
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
